Martin Dreyling

Active 1994–2025

189
Papers
32,297
Citations
89
h-index
177
i10-index

Citations

Citations per year for Martin Dreyling1990: 1 citations1994: 3 citations1995: 2 citations1996: 6 citations1997: 2 citations1998: 7 citations1999: 8 citations2000: 10 citations2001: 7 citations2002: 10 citations2003: 9 citations2004: 4 citations2005: 25 citations2006: 21 citations2007: 65 citations2008: 80 citations2009: 110 citations2010: 106 citations2011: 166 citations2012: 187 citations2013: 181 citations2014: 235 citations2015: 240 citations2016: 248 citations2017: 291 citations2018: 259 citations2019: 887 citations2020: 913 citations2021: 965 citations2022: 935 citations2023: 862 citations2024: 1,276 citations2025: 561 citations2026: 7 citations1991–1993: no citations, so these years are not shown

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 2,786 citing papers, 24.2% of this breakdownGermany: 852 citing papers, 7.4% of this breakdownItaly: 775 citing papers, 6.7% of this breakdownFrance: 750 citing papers, 6.5% of this breakdownUnited Kingdom: 724 citing papers, 6.3% of this breakdownChina: 682 citing papers, 5.9% of this breakdownSpain: 546 citing papers, 4.7% of this breakdownCanada: 426 citing papers, 3.7% of this breakdownSwitzerland: 391 citing papers, 3.4% of this breakdownAustralia: 330 citing papers, 2.9% of this breakdownNetherlands: 309 citing papers, 2.7% of this breakdownJapan: 252 citing papers, 2.2% of this breakdown
0%24.2%Other 23.4%

Fields

  • Medicine84.1%
  • Biochemistry, Genetics and Molecular Biology10.5%
  • Immunology and Microbiology2.9%
  • Neuroscience0.8%
  • Chemistry0.4%
  • Computer Science0.3%
  • Other1%

Topics

  • Lymphoma Diagnosis and Treatment19%
  • Chronic Lymphocytic Leukemia Research8.8%
  • CAR-T cell therapy research8.7%
  • Viral-associated cancers and disorders4.8%
  • CNS Lymphoma Diagnosis and Treatment4.1%
  • Cutaneous lymphoproliferative disorders research2.9%
  • Other51.7%

Coauthors

All papers

Open in search
  1. The International Consensus Classification of Mature Lymphoid Neoplasms: a report from the Clinical Advisory Committee

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jeffrey I. Cohen, Francesco d’Amore, Andrew Davies, Brunangelo Falini, Irene M. Ghobrial, John R. Goodlad, John G. Gribben, Eric D. Hsi, Brad S. Kahl, Won-Seog Kim, Shaji Kumar, Ann S. LaCasce, Camille Laurent, Georg Lenz, John P. Leonard, Michael P. Link, Armando López‐Guillermo, María‐Victoria Mateos, Elizabeth Macintyre, Ari Melnick, Franck Morschhauser, Shigeo Nakamura, Marina Narbaitz, Astrid Pavlovsky, Stefano Pileri, Miguel Á. Piris, Barbara Pro, S. Vincent Rajkumar, Steven T. Rosen, Birgitta Sander, Laurie H. Sehn, Margaret A. Shipp, Sonali M. Smith, Louis M. Staudt, Catherine Thieblemont, Thomas Tousseyn, Wyndham H. Wilson, Tadashi Yoshino, Pier Luigi Zinzani, Martin Dreyling, David W. Scott, Jane N. Winter, Andrew D. Zelenetz - Blood 2022 cited by 1,506

  2. Tisagenlecleucel in adult relapsed or refractory follicular lymphoma: the phase 2 ELARA trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Rakesh Awasthi, Aisha Masood, Oezlem Anak, Stephen J. Schuster, Catherine Thiéblemont - Nature Medicine 2021 cited by 527

  3. CAR-HEMATOTOX: a model for CAR T-cell–related hematologic toxicity in relapsed/refractory large B-cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2021 cited by 441

  4. Second-Line Tisagenlecleucel or Standard Care in Aggressive B-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Mohamed A. Kharfan‐Dabaja, Simon Newsome, Evgeny Degtyarev, Rakesh Awasthi, Christopher del Corral, Giovanna Andreola, Aisha Masood, Stephen J. Schuster, Ulrich Jäger, Peter Borchmann, Jason R. Westin - New England Journal of Medicine 2021 cited by 520

  5. Tafasitamab plus lenalidomide in relapsed or refractory diffuse large B-cell lymphoma (L-MIND): a multicentre, prospective, single-arm, phase 2 study

    Authors: , , , , , , , , , , , , , , , , - The Lancet Oncology 2020 cited by 519

  6. Revised Response Criteria for Malignant Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2007 cited by 4,448

  7. Targeting BTK with Ibrutinib in Relapsed or Refractory Mantle-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Kristie A. Blum - New England Journal of Medicine 2013 cited by 1,687

  8. Brentuximab vedotin with chemotherapy for CD30-positive peripheral T-cell lymphoma (ECHELON-2): a global, double-blind, randomised, phase 3 trial

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lorenz Trümper, David M. Aboulafia, Ranjana H. Advani, Önder Alpdoğan, Kiyoshi Ando, Luca Arcaini, Luca Baldini, Naresh Bellam, Nancy L. Bartlett, David Belada, Dina Ben Yehuda, Fabio Benedetti, Peter Borchman, Dominique Bordessoule, Pauline Brice, Javier Briones, Dolores Caballero, Angelo Michele Carella, Hung Chang, June Weon Cheong, Seok‐Goo Cho, Ilseung Choi, Sylvain Choquet, Andrei Coliţă, Angela Giovanna Congui, Francesco d’Amore, Nam H. Dang, Kelly Davison, Sophie de Guibert, Peter de Nully Brown, Vincent Delwail, Judit Demeter, Francesco Di Raimondo, Young Rok, Eva Domingo, Michael G. Douvas, Martin Dreyling, Thomas Ernst, Michelle A. Fanale, Keith Fay, Tatyana Feldman, Silvia Ferrero, Ian W. Flinn, Andres Forero‐Torres, Christopher P. Fox, Jonathan W. Friedberg, Noriko Fukuhara, José A. García‐Marco, Jorge Gayoso Cruz, José Codina, Rémy Gressin, Andrew Grigg, Ronit Gurion, Jacob Haaber Christensen, Corinne Haïoun, Roman Hájek, Mathias Hänel, Kiyohiko Hatake, Robert Hensen, Netanel A. Horowitz, Steven M. Horwitz, Andreas Hüttmann, Árpád Illés, Tim Illidge, Kenichi Ishizawa, Miguel Islas‐Ohlmayer, Eric D. Jacobsen, Murali Janakiram, Wojciech Jurczak, Mark Kaminski and 69 more - The Lancet 2018 cited by 726

  9. Lisocabtagene maraleucel in follicular lymphoma: the phase 2 TRANSCEND FL study

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Jessica Papuga, Jinender Kumar, Loretta J. Nastoupil - Nature Medicine 2024 cited by 130

  10. Integration of gene mutations in risk prognostication for patients receiving first-line immunochemotherapy for follicular lymphoma: a retrospective analysis of a prospective clinical trial and validation in a population-based registry

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Michael Unterhalt, Wolfgang Hiddemann, Randy D. Gascoyne, David M. Weinstock, Oliver Weigert - The Lancet Oncology 2015 cited by 613

  11. Genomic profiling for clinical decision making in lymphoid neoplasms

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Falko Fend, Philippe Gaulard, Paolo Ghia, John G. Gribben, Olivier Hermine, Daniel J. Hodson, Eric D. Hsi, Giorgio Inghirami, Elaine S. Jaffe, Kennosuke Karube, Keisuke Kataoka, Wolfgang Hiddemann, Won Seog Kim, Rebecca L. King, Young Hyeh Ko, Ann S. LaCasce, Georg Lenz, José I. Martín‐Subero, Miguel Á. Piris, Stefania Pittaluga, Laura Pasqualucci, Leticia Quintanilla‐Martínez, Scott J. Rodig, Andreas Rosenwald, Gilles Salles, Jesús F. San Miguel, Kerry J. Savage, Laurie H. Sehn, Gianpietro Semenzato, Louis M. Staudt, Steven H. Swerdlow, Constantine S. Tam, Judith Trotman, Julie M. Vose, Oliver Weigert, Wyndham H. Wilson, Jane N. Winter, Catherine J. Wu, Pier Luigi Zinzani, Emanuele Zucca, Adam Bagg, David W. Scott - Blood 2022 cited by 161

  12. Phosphatidylinositol 3-Kinase Inhibition by Copanlisib in Relapsed or Refractory Indolent Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Journal of Clinical Oncology 2017 cited by 398

  13. Polatuzumab vedotin or pinatuzumab vedotin plus rituximab in patients with relapsed or refractory non-Hodgkin lymphoma: final results from a phase 2 randomised study (ROMULUS)

    Authors: , , , , , , , , , , , , , , , , , , , , , , - The Lancet Haematology 2019 cited by 249

  14. Durable response after tisagenlecleucel in adults with relapsed/refractory follicular lymphoma: ELARA trial update

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Aiesha Zia, Rakesh Awasthi, Xia Han, Davide Germano, Darragh O’Donovan, Roberto Ramos, Harald J. Maier, Aisha Masood, Catherine Thiéblemont, Stephen J. Schuster - Blood 2024 cited by 93

  15. PI3Kδ Inhibition by Idelalisib in Patients with Relapsed Indolent Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , - New England Journal of Medicine 2014 cited by 1,062

  16. The genomic and transcriptional landscape of primary central nervous system lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Lorenz Trümper, Ioannis Anagnostopoulos, Dido Lenze, Ralf Küppers, Michael Hummel, Clemens A. Schmitt, Otmar D. Wiestler, Stephan Wolf, Andreas Unterberg, Roland Eils, Christel Herold‐Mende, Benedikt Brors, Coordination (C1), Reiner Siebert, Susanne Wagner, Andrea Haake, Julia Richter, Gesine Richter, Roland Eils, Chris Lawerenz, Jürgen Eils, Jules N. A. Kerssemakers, Christina Jaeger-Schmidt, Ingrid Scholz, Anke Bergmann, Christoph Borst, Friederike Braulke, Birgit Burkhardt, Alexander Claviez, Martin Dreyling, Sonja Eberth, Hermann Einsele, Norbert Frickhofen, Siegfried Haas, Martin‐Leo Hansmann, Dennis Karsch, Nicole Klepl, Michael Kneba, Jasmin Lisfeld, Luisa Mantovani‐Löffler, Marius Rohde, German Ott, Christina Stadler, Peter Staib, Stephan Stilgenbauer, Thorsten Zenz, Normal Cells (WPN), Martin‐Leo Hansmann, Dieter Kube, Pathology and Analyte Preparation (WP2-3), Siegfried Haas, Wolfgang Hiddemann, Ulrike Kostezka, Peter Möller, Andreas Rosenwald, German Ott, Monika Szczepanowski, Sequencing and genomics (WP4-7), Ole Ammerpohl, Sietse Aukema, Vera Binder, Arndt Borkhardt, Andrea Haake, Jessica I. Hoell, Ellen Leich, Peter Lichter, Cristina López, Inga Nagel, Jordan Pischimariov, Bernhard Radlwimmer and 27 more - Nature Communications 2022 cited by 140

  17. Characterization of atrial fibrillation adverse events reported in ibrutinib randomized controlled registration trials

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Haematologica 2017 cited by 258

  18. Ibrutinib plus Bendamustine and Rituximab in Untreated Mantle-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Martin Dreyling - New England Journal of Medicine 2022 cited by 216

  19. Ibrutinib combined with immunochemotherapy with or without autologous stem-cell transplantation versus immunochemotherapy and autologous stem-cell transplantation in previously untreated patients with mantle cell lymphoma (TRIANGLE): a three-arm, randomised, open-label, phase 3 superiority trial of the European Mantle Cell Lymphoma Network

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , Judith Dierlamm, Christiane Pott, Wolfgang Hiddemann, Döndü Gözel, Christian Schmidt, Michael Unterhalt, Marco Ladetto, Eva Hoster - The Lancet 2024 cited by 136

  20. A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , - Blood 2007 cited by 971

  21. The CAR‐HEMATOTOX score identifies patients at high risk for hematological toxicity, infectious complications, and poor treatment outcomes following brexucabtagene autoleucel for relapsed or refractory MCL

    Authors: , , , , , , , , , , , , , , , , , , , - American Journal of Hematology 2023 cited by 46

  22. Ibrutinib plus Venetoclax for the Treatment of Mantle-Cell Lymphoma

    Authors: , , , , , , , , , , , , , , , , - New England Journal of Medicine 2018 cited by 429

  23. Postibrutinib outcomes in patients with mantle cell lymphoma

    Authors: , , , , , , , , , , , , , , , , , , , , , , , , , , - Blood 2016 cited by 283

  24. Richter transformation in chronic lymphocytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials

    Authors: , , , , , , , , , , , , , , , , , , - Leukemia 2020 cited by 110